In a randomized trial involving SLE patients, significant reduction in NET complexes was observed in individuals with the STAT4 risk allele who received Tofacitinib treatment, while no impact was observed in STAT4 risk allele-negative patients or those in the placebo group (134). Here, STAT4 is linked to systemic lupus erythematosus.